Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

UCART-22

Alternative Names: ucart-22, ucart22, ucart 22, u cart 22
Clinical Status: Active
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

UCART-22 is being developed by Cellectis for the treatment of patients with Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04150497?term=UCART-22&draw=2&rank=1)

Mechanisms of Action: CAR-T,CD22

Novel Mechanism: Yes

Modality: CAR-T

Route of Administration: N/A

FDA Designation: Orphan Drug - Acute Leukemia|Acute Lymphoid Leukemia|Leukemia|Lymphoid Leukemia
Orphan Drug - Acute Lymphoid Leukemia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cellectis
Company Location: PARIS, LLE-DE-FRANCE I0 75013
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UCART-22

Countries in Clinic: France, Italy, Spain, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

  • Clinical Outcomes Expected - Cellectis announced they will present P1 Acute Lymphoid Leukemia results in 3Q25 for UCART-22
  • Clinical Outcomes Expected - Cellectis announced they will present P1 Leukemia results in YE25 for UCART-22
  • Clinical Outcomes Reported - Cellectis announced they will present P1 Acute Lymphoid Leukemia results in YE24 for UCART-22

Highest Development Phases

Phase 2: Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
BALLI-01

P2

Active, not recruiting

Leukemia

2040-08-08

2022-03-13

Treatments
BALLI-01

P2

Recruiting

Lymphoma, B-Cell|Acute Lymphoid Leukemia|B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

2026-01-31

18%

2024-08-27

Primary Completion Date|Primary Endpoints
2022-502305-15-00

P2

Recruiting

Acute Lymphoid Leukemia|B-Cell Leukemia

2039-01-12

2025-05-02

Treatments

Recent News Events

Date

Type

Title

12/10/2024

News Article

 Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

08/01/2024

News Article

 FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

07/25/2024

News Article

 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

06/04/2024

News Article

 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions